EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AbCellera Biologics's enterprise value is $1,708.95 Mil.
AbCellera Biologics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-167.02 Mil. Therefore, AbCellera Biologics's EV-to-EBITDA for today is -10.23.
The historical rank and industry rank for AbCellera Biologics's EV-to-EBITDA or its related term are showing as below:
ABCL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -50.05 Med: -1.08 Max: 2202.26
Current: -10.23
During the past 8 years, the highest EV-to-EBITDA of AbCellera Biologics was 2202.26. The lowest was -50.05. And the median was -1.08.
ABCL's EV-to-EBITDA is ranked worse than 100% of 391
companies
in the Biotechnology industry
Industry Median: 13.14
vs ABCL: -10.23
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AbCellera Biologics's PE Ratio (TTM) for today is calculated as:
AbCellera Biologics's share price for today is $6.79.
AbCellera Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.480.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for AbCellera Biologics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AbCellera Biologics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's EV-to-EBITDA falls into.
AbCellera Biologics's current Enterprise Value is $1,708.95 Mil.
AbCellera Biologics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-167.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (ABCL) has a EV-to-EBITDA of -10.23 as of Jul. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AbCellera Biologics. According to the industry distribution chart, AbCellera Biologics ranks #999999 out of 391 companies in the Biotechnology industry.
Is AbCellera Biologics' EV-to-EBITDA too high?
AbCellera Biologics' current EV-to-EBITDA is -10.23. Based on the distribution chart, AbCellera Biologics ranks #999999 out of 391 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' EV-to-EBITDA compare to AGIO and KOD?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #999999 out of 391 companies for EV-to-EBITDA. This places AbCellera Biologics in the lower half of its industry. The industry median EV-to-EBITDA is 13.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.14, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AbCellera Biologics. For the Biotechnology industry, the median EV-to-EBITDA is 13.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current EV-to-EBITDA is -10.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.38, compared to a current price of $6.79 — trading 26.2% above its estimated fair value. The current EV-to-EBITDA is -10.23. AbCellera Biologics' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current EV-to-EBITDA is -10.23 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $6.79 is trading 26.2% above its estimated GF Value™ of $5.38.
GuruFocus considers AbCellera Biologics to be Modestly Overvalued.
Key valuation signals for ABCL:
EV-to-EBITDA: -10.23
GF Value™: $5.38 vs. price of $6.79 (26.2% above fair value)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score
Get the complete analysis for ABCL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
